Dedicated to small-molecule therapeutics for neuromuscular diseases

Santhera
Hammerstrasse 47
4410
Liestal
4410 Liestal
Auf Karte anzeigen
061 906 89 54
061 906 89 51
office@santhera.com
www.santhera.com
Firmenbeschrieb
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of severe neuromuscular diseases. Santhera’s vision is to become a leading specialty pharmaceutical company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indications with no current therapy. Santhera currently has four clinical stage development programs, three of which are investigating its lead compound, SNT-MC17/idebenone, in the treatment of Friedreich’s Ataxia (FRDA), Duchenne Muscular Dystrophy (DMD) and Leber’s Hereditary Optic Neuropathy (LHON). The fourth clinical program is investigating JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson’s Disease (DPD) in cooperation with Juvantia. The most advanced program, SNT-MC17/idebenone in FRDA, has entered pivotal Phase III clinical trials; the other clinical programs are in Phase II. There are currently no effective treatments available for FRDA. Treatments currently in use for DMD and DPD are generally viewed by the medical community as inadequate. Santhera’s drug pipeline comprises another three preclinical programs in cancer cachexia, DMD and diabetes (out licensed to Biovitrum). Santhera was formed in 2004 through a business combination of MyoContract AG and Graffinity Pharmaceuticals AG. The Company is based in Liestal, Switzerland. Santhera has attracted investment from leading global industry investors including NGN Capital, Merlin Biosciences Limited, 3i Group plc, Varuma AG, Oxford Bioscience Partners, the Novartis Venture Fund, Heidelberg Innovation, GIMV, Carnegie Asset Management, TechnoStart, Clariden Biotechnology Fund, the Swiss Foundation for Research on Muscle Diseases, The Dow Chemical Company, Altana Innovationsfonds, tbg, and private investors. The company's experienced and entrepreneurial management team is dedicated to making Santhera a leading biopharmaceutical company in neuromuscular disease through: Successful commercialization of the Company’s lead product SNT-MC17/idebenone which is in a European Phase III clinical trial for Friedreich’s Ataxia. It is also being tested in a Phase IIa clinical trial for Duchenne Muscular Dystrophy Creation of a robust pipeline in the field of neuromuscular disease through Santhera’s integrated drug discovery, research and development skill set Strategic in-licensing of products that fit the company’s criteria of marketability and value-creation Launching and marketing of niche products via Santhera's own sales and marketing force Out-licensing of products that address large patient populations Operational excellence and solid financingGründungsjahr
2004
Rechtsform
Aktiengesellschaft (AG)
Anzahl Mitarbeiter
100
Eintrag erstellt: 05.10.2006, Letzte Änderung: 05.10.2006
